Acute promyelocytic leukemia (APL) is characterized by a recurrent translocation between chromosomes 15 and 17, resulting in the fusion of the promyelocytic leukemia gene (PML) to the retinoic acid receptor a gene (RARa). 1 Among APL cases with a PML-RARa rearrangement, chromosome 15 breakpoints fall within three breakpoint cluster regions (bcrs): bcr1 and bcr3 correspond to PML introns 6 and 3, respectively, whereas bcr2 is located within PML exon 6, or very occasionally within PML exon 5. On the contrary, a single RARa breakpoint region occurs within intron 2.
2
A bcr1 breakpoint is reported in approximately 55% of patients and results in an mRNA fusion of PML exon 6 to RARa exon 3, conventionally referred to as the long (L) isoform. A bcr3 breakpoint occurs in approximately 40% of cases and results in an mRNA fusion of PML exon 3 to RARa exon 3, referred to as the short (S) isoform. A bcr2 breakpoint occurs in approximately 5% of patients and usually results in a tripartite mRNA fusion in which part of PML exon 6 is fused to an insert sequence and then to RARa exon 3, where the insert is usually between 3 and 127 base pairs long and has been presumed to be derived from RARa intron 2. Some cases have no inserted nucleotides and instead use a cryptic splice site within PML exon 6 to splice part of this exon in frame to RARa exon 3. Collectively, these transcripts are referred to as the variable (V) isoform. [2] [3] We report an APL case showing a different genomic and molecular rearrangement at relapse from those observed at the onset of disease.
A 39-year-old man was admitted to our hospital in October 2002 with hematuria and diffuse bruising. Blood analysis Letters to the Editor showed hemoglobin 11.8 g l À1 , leukocytes 5.3 Â 10 9 l À1 (neutrophils: 8%; lymphocytes: 5%; monocytes: 3%; promyelocytes: 84%) and platelets 21 Â 10 9 l À1 . The international normalized ratio of prothrombin time was 1.42 and fibrinogen was 59 mg per 100 ml.
A bone marrow aspirate disclosed hyperplasia with 87% of abnormal promyelocytes. Conventional cytogenetic analysis revealed that the karyotype was 46, XY, t(15;17)(q22;q21). Fluorescence in situ hybridization analysis was performed on a bone marrow sample at diagnosis. The bacterial artificial chromosome clone RP11-247C2 (15q24.1) and phage P1 artificial chromosome (PAC) RP5-1112G21 (17q21.2) were selected to identify the PML gene on chromosome 15 and RARa gene on chromosome 17, respectively. These probes generate two clear fusion signals on der(15) and on der(17) chromosomes in addition to single signals on normal 15 and 17 chromosomes when hybridized on metaphases of an APL patient with the t(15;17) rearrangement. In our patient, fluorescence in situ hybridization experiment with probes specific for PML and RARa genes revealed the presence of a variant t(15;17;22) translocation ( Figure 1a) ; in fact, only one fusion signal was present on the der(15) chromosome and the clone RP11-247C2 (15q24.1) specific for the PML gene hybridized also on the der(22) chromosome. Additional bacterial artificial chromosome/phage P1 artificial chromosome clones belonging to chromosome 22 were selected to characterize the rearrangement. The database Letters to the Editor from the University of California, Santa Cruz (UCSC, http:// www.genome.ucsc.edu) was queried for bacterial artificial chromosome/phage P1 artificial chromosome probe locations. The mapping of each clone was firstly tested on normal human metaphases. A cohybridization experiment using the telomeric clone CTA-799F10 (22q13.33) and the phage P1 artificial chromosome RP5-1112G21 (17q21.2) confirmed the involvement of chromosome 22 in the complex rearrangement, as a fusion signal was observed on der(17) (Figure 1b) . The chromosome 22 breakpoint was mapped between the two clones RP11-205J5 (22q11.23) and RP11-254G15 (22q11.23) because the former was retained on der(22) while the latter was translocated on der(17). Therefore, according to the molecular cytogenetic rearrangement analysis, the karyotype can be rewritten as 46, XY, t(15;17;22) (q24.1;q21.2;q11.23) (Figure 1c) .
Molecular analysis performed by RT-PCR revealed that the PML-RARa fusion mRNA corresponded to the bcr1 isoform (L-form). The search for fms-like tyrosine kinase 3 (FLT3) gene mutation revealed the presence of a D835 point mutation.
To assess the presence of fusion transcripts involving the 5 0 RARa and/or 3 0 PML genes, RACE-PCR experiments were performed using the SMART RACE cDNA amplification kit (Clontech Laboratory Inc., Mountain View, CA, USA). In detail, 5 0 RACE was carried out using a primer specific for PML exon 7 (5 0 -GGCATCTGAGTCTTCCGAGCTGCTG-3 0 ), whereas a primer located in RARa exon 2 (5 0 -CCGCATCTACAAGCCTTGCTTT GTCT-3 0 ) was selected to perform 3 0 RACE-PCR. RACE-PCR experiments did not reveal the involvement of other known genes in the complex rearrangement (data not shown).
According to these data, a diagnosis of APL (FAB-M3) was made. Idarubicin and trans-retinoic acid were started following the All-trans retinoic acid þ Idarubicin (AIDA) protocol of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) group. 4 In November 2002, the patient achieved a complete clinical and molecular remission; from this time sequential molecular monitoring was carried out every 3 months. In January 2007, he showed molecular relapse; at this point the molecular cytogenetic analysis revealed a classic t(15;17) in all analyzed metaphases (data not shown) and RT-PCR showed that this time the PML-RARa fusion transcript corresponded to the bcr2 instead of the bcr1 isoform detected at diagnosis. Therefore, sequencing reactions were performed by fluorescence dye terminator and ABI 3730 DNA sequencer to assess that the PCR product was effectively a V-form transcript. Sequence analysis confirmed that the PML breakpoint was located within exon 6. Moreover, to exclude the possibility that the fusion transcript detected at diagnosis was a V-form with RARa intron-2 nucleotides mimicking the size of the bcr1 isoform, we performed sequence analysis on the PCR product obtained at the diagnosis. The sequencing results showed that the breakpoint occurred within PML intron 6, confirming that the isoform transcript at diagnosis was indeed a bcr1. In March 2007, the patient presented hematological relapse and was again treated according to the AIDA protocol. At the time of relapse, the search for FLT3 mutations did not reveal alterations. In April 2007, he reached hematological and molecular remission. He is currently in complete remission.
In this paper, we describe an APL case characterized by different genomic and molecular rearrangements at onset and at relapse. To our knowledge, similar APL cases have never been reported in literature. Our case raises at least three points of discussion: (1) the meaning of two different chromosomal rearrangements in the different phases of APL, (2) the appearance of a bcr transcript type at relapse distinct to the one observed at diagnosis, and (3) the disappearance of the FLT3 mutation at relapse.
Concerning the first point, it is possible that the complex rearrangement t(15;17;22) observed at diagnosis may have been caused by a stepwise translocation derived from the typical t(15;17), as described in previous report. 5 Therefore, in this case, it is more likely that the complex translocation is the result of an advanced phase of the stem cell transformation process, selecting the clone with the best proliferation advantage. In this respect, it has been reported that complex translocations in APL as well as many chromosome abnormalities additional to the classic t(15;17) may render leukemic cells poorly responsive to therapy, and therefore they could be important prognostic factors for the outcome in APL patients. 6 The second point of discussion concerns the molecular transcript type switch. In our case, we performed direct sequencing on the transcript type (bcr1) detected at diagnosis to rule out the possibility that a large sequence capture, produced by a mechanism of illegitimate recombination, could be responsible for a bcr2 mimicking in length the bcr1-type transcript. We later performed sequencing analysis also on the transcript type (bcr2) observed at relapse to exclude the possibility of a bcr1-spliced variant transcript; in fact, it has been reported that as the PML gene consists of nine exons, from which exons 4-6 may be skipped, in the bcr1-type, several spliced transcripts are generated. 7 Therefore, it could be supposed that the bcr-type transcript switch reported in our case may be in conjunction with the different chromosomal rearrangement at onset and at relapse of APL.
The third point is about the FLT3 mutation observed at diagnosis but that had disappeared at relapse; the loss of mutation may reflect two facts: (1) the FLT3 mutation seems to be a late event of APL; 8 in this context, its appearance fits with the diagnosis of APL at the time, in our case, when the clonal evolution occurred (indicated by the t(15;17;22)); (2) the selective advantage provided by this kind of alteration was replaced, at relapse, by other unknown genetic and/or molecular aberrations.
In summary, our case may reveal a dynamic clonal situation in APL during which at diagnosis there was a complex t(15;17) rearrangement, bcr1 molecular transcript and FLT3 point mutation, whereas at relapse there were different genomic and molecular features. We hypothesize that chemotherapy induction exerted a 'resetting-effect' on the leukemic cell due to which, at relapse, the emerging clone had a classic t(15;17), a different bcr transcript, probably resulting from the different chromosomal rearrangement, and the FLT3 mutation had disappeared.
Our report suggests that a careful approach, in addition to a workup, is needed to clarify the cytogenetic and molecular events of the pathogenesis of APL.
The JAK2-V617F mutation is mostly found in classic Philadelphia-chromosome negative myeloproliferative diseases, such as polycythemia vera, essential thrombocytosis (ET) and myeloid metaplasia/myelofibrosis. However, it remains unclear whether the JAK2-V617F mutation is the essential and sufficient molecular event leading to myeloproliferative disease (MPD). Several observations tend to support the existence of a pre-JAK2 mutated clone: (i) the diversity of hematological phenotypes associated with the mutation, which contrasts with the stereotyped phenotype of Philadelphia-positive chronic myelogenous leukemia, (ii) familial cases of MPDs where the JAK2-V617F mutation is thought to be an event occurring on a background of already clonal hematopoiesis or on a germline mutated cell predisposed to acquire new somatic mutations 1,2 and (iii) clonality studies in cohorts of JAK2-V617F-positive MPDs. 3, 4 Furthermore, the fact that the leukemic blasts of acute myeloid leukemia (AML) derived from JAK2-V617F-positive MPDs are often negative for the mutation 5, 6 raises the question whether MPD and AML arise from two different progenitor cells or are derived from a common ancestor in which the JAK2-V617F mutation is a late event leading to MPD.
Here, we describe the unusual case of a patient diagnosed with de novo AML in which the allogeneic transplantation setting allowed for the unique observation of the sequence of events leading to the acquisition of the JAK2-V617F mutation, and the possible multistep pathogenesis underlying the development of secondary AML derived from a preexisting MPD.
A 50-year-old man was diagnosed in March 2000 with AML FAB-M2 CD7 þ characterized by an unfavorable hyperploid complex karyotype (53XY þ 2, þ 6, þ 8, þ 8, þ 13, þ 14, þ 18). Standard cytarabine-daunorubicin 3-7 induction led to a complete remission and a normal karyotype. This was followed by a high-dose cytarabine and daunorubicine consolidation. 3, 4 The patient received a 6/6 HLA-matched allogeneic stem cell transplant from his sister. Immediately prior to transplant, karyotype and bone marrow studies were normal, while the complete blood count showed normocytic anemia. The conditioning regimen consisted of a busulphan-cyclophosphamide long course protocol with cyclosporine and methotrexate short course as prophylaxis of graft-versus-host disease (GVHD). The patient was infused with a peripheral stem cell graft of 9.9 Â 10 6 CD34 per kg and 19.7 Â 10 7 CD3 per kg. Neutrophil engraftment took place on day 16 and the patient was discharged on day 24. At 5 months after transplant, the patient presented with extensive chronic GVHD (cGVHD), which was persistent and required triple immunosuppressive therapy. At 35 months after transplant, the patient started to exhibit leucocytosis, followed by thrombocytosis. Progression of both the leucocytosis and thrombocytosis, attaining 85.3 Â 10 9 l À1 and 856 Â 10 9 l
À1
, respectively, led to the initiation of hydroxyurea 500 mg daily at 42 months after transplant, which normalized his blood counts. The patient refused a second allogeneic transplantation. At 54 months after transplant, AML relapse was diagnosed on the basis of an 80 and 19% blastosis in the peripheral blood and bone marrow aspiration, respectively. The karyotype was normal. The patient died at 55 months posttransplantation from a septic choc occurring during his induction therapy.
This case of a patient transplanted for de novo AML and developing post-myeloablative transplantation, an MPD and ultimately leukemia relapse was further analyzed. Samples were obtained with informed consent from the patient and Institutional Review Board approval. Chimerisms were performed by PCR amplification of short-tandem repeat polymorphic markers on DNA of polymorphonuclear cells, T-cells and mononuclear fraction at different time points after transplantation. Cytogenetic studies were performed on the marrow pre-transplantation, and at 26, 37 and 54 months post-transplantation using standard procedures. The chimerism analysis shown in Figure 1 revealed that complete donor hematopoiesis was present 1 month after transplant in the peripheral blood polymorphonuclear cells, and remained so for 24 months, where routine
